Introduction
The production of radioisotopes for use in biomedical procedures such as diagnostic imaging and/or therapeutic treatments is achieved through nuclear reactions in reactors or from charged particle bombardment in accelerators. In reactors the nuclear reactions are initiated with neutrons while in accelerators the typical charged particle reactions utilize protons although deuterons and α−particles play a role. While the generation of the 99 Mo/ 99m Tc generator is performed in reactors and the procedures making use of this generator account for nearly 90% of all Nuclear Medicine procedures, this paper will focus on the use of low energy (<50 MeV protons) accelerators for the production of radioisotopes.
One clear advantage that accelerators possess is the fact that, in general, the target and product are different chemical elements making it possible to find suitable chemical or physical means for separation. This leads to the potential of high specific activities. In addition, at low energy there are fewer isotopic impurities that also contribute to higher specific activities.
The availability of accelerators fits into several categories. First there are universitybased cyclotrons that are typically multi-particle machines with energies around 30-50 MeV. Then there are the hospital-based machines, which are generally dedicated to the production of the standard PET radioisotopes ( 11 C, 13 N,
15
O, and 18 F). These cyclotrons accelerate protons in the 10-19 MeV range and some also produce deuterons with an energy of about ½ that of the proton (5-9 MeV). The cyclotrons used by industry for large-scale production are typically 30 MeV proton only machines although there are some using lower energies for dedicated production of 103 Pd (see below).
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Several national labs from around the world are involved in the production radioisotopes that are not produced by the commercial radioisotope producers such as the 82 Sr/ 82 Rb generator and 68 Ge. These machines are typically operated at greater than 100 MeV and accelerate protons with a beam current exceeding 150-200 µA. The limitations of these high-energy facilities include the difficulty associated with scheduling since most of these facilities are machines that have been built around Nuclear Physics programs with medical applications using the accelerator in parasitic mode or when the physics program is not operational. Another problem is the range of products produced. Because of the high energy of the proton beam, the dominant reaction mechanism is spallation, which produces not only many different atomic species but also many isotopes of the same element. This not only provides possible radioactive contaminants but also stable species that can affect the specific activities of the desired product. A more detailed discussion of these facilities can be found elsewhere in these proceedings.
Radioisotopes for Imaging
While there is a wide range of radioisotopes that are used in imaging, a relatively small number make up the vast majority of all studies in SPECT and PET imaging. Tc at an accelerator can never compete with the extremely low costs of producing it at a reactor. While there is concern about the ability to build new reactors and thus jeopardizing the availability of this important isotope, the recent construction of reactors in Canada dedicated to 99 Mo production removes this concern for the present.
Iodine-123 has been of interest for nearly 3 decades because of its unique chemistry that makes it possible to attach this isotope to a wide variety of molecules and the γ-COMO paper -Production of radioisotopes1.doc submitted to World Scientific : 10/12/2001 : 11.31 3/6 ray energy (159 keV) that is matched well to present day cameras. The ability to produce this isotope in high purity from enriched 124 Xe targets made it possible to ship 123 I over long distances and still have high specific activity 123 I available for labeling. However, the production costs are still very high in comparison to other radioisotopes, which will make its use limited for the foreseeable future. Thalium-201 has been extensively used for more than 25 years. Over this period there have been numerous reports of its demise, yet the growth in demand for this isotope is still upwards.
The remaining isotopes listed are used in PET imaging. Carbon-11 is extremely attractive because, in principle, one can replace an existing carbon atom in the molecule of interest with the radioactive isotope. However, because of the short half-life, its availability will be limited to those sites possessing an accelerator or near to one. The demand for 18 F exceeds it availability. To overcome this shortage, a number of central distribution centers have been placed in large metropolitan areas in North America, Europe and Japan. Although several nuclear reactions are provided, the (p,n) reaction is the route of choice for producing large quantities of The other two isotopes are candidates for both PET imaging and possible use in therapy (see below). The interest in these two is primarily related to the relatively long half-lives. Such properties would enable studies to be performed where the kinetics are slow and exceed the ability to image with 18 F. The disadvantages include low production rate ( 124 I) and the need for expensive enriched target material ( 64 Ni, 124 Te). Recent results from Washington University in St. Louis have shown that even with the high-energy β-particles associated with 124 I decay and other photons in coincidence with the β-decay, they can still be imaged at high resolution ( 64 Cu).
Radioisotopes for Therapy
The idea of a radioisotope used in therapy is based on the desire to link a radionuclide which has a high linear energy transfer associated with is decay products such as Auger electrons, β-particles or α-particles to a biologically active molecule that can be directed to a tumor site. Since the β−emitting radionuclides are neutron rich they have, in general, been produced in reactors. Table 3 . Listing of radionuclides that have been proposed for use as possible radiotoxic isotopes for treating cancer.
Most of these radionuclides are produced in a reactor although a few are best produced in via charged particle reactions. Table 4 provides the charged particle nuclear reactions that can be used for selected radiotoxic nuclides.
The attractive feature of 77 Br is its chemical versatility in addition to its half-life. Production rates are relatively low and purity may be an issue since 76 Br is often coproduced. The demand for 103 Pd, which is used in treating prostate cancer, is continuing to grow. A large number of low energy (19 MeV) cyclotrons are dedicated solely to the production of this isotope.
Rhenium-186 is attractive for a number of reasons. It has the desirable physical characteristics of being a β-emitter with a useful half-life (90 hours) and a γ-ray
